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A clone expressing a 35.5-kDa recombinant treponemal protein was isolated from a genomic DNA library
constructed from Treponema pallidum street strain 14. Polyclonal antiserum raised against the recombinant
protein reacted with a corresponding native protein of comparable size in T. pallidum that is specific to the
pathogenic treponemes. Radiolabeling of the recombinant protein with [3H]palmitate demonstrated that it is
lipid modified. Like other recently characterized T. pallidum lipoproteins, the 35.5-kDa lipoprotein partitioned
into the detergent phase from T. pallidum cells fractionated with Triton X-114, suggesting that it is an integral
membrane protein. Processing of the recombinant 35.5-kDa lipoprotein from a precursor form to a smaller
mature form was not evident in pulse-chase experiments. However, pretreatment of Escherichia coli cells
expressing the 35.5-kDa lipoprotein with inhibitors of protein processing or translocation revealed the existence
of a higher-molecular-mass precursor. Gene fusion studies with the transposon TnphoA demonstrated the
presence of an export signal in the 35.5-kDa lipoprotein that promotes the extracytoplasmic localization of a
35.5-kDa lipoprotein-PhoA hybrid.
Although syphilis has been recognized as a clinical entity
for centuries, knowledge of the biology and pathogenicity of
the etiologic agent, Treponema pallidum, remains limited
because of the inability to continuously culture the spiro-
chete in vitro (14). Since cultivation of T. pallidum in
experimentally infected rabbits provides only limited quan-
tities of organisms, investigators have made use of recombi-
nant DNA and monoclonal antibody technologies to facili-
tate the study of this bacterium. Genomic libraries of T.
pallidum Nichols DNA have been constructed, and the
protein products expressed from a number of cloned genes
have been identified and characterized (1, 26, 41, 50). Most
of these proteins were selected on the basis of reactivity with
syphilitic sera from infected humans or experimentally in-
fected rabbits or with monoclonal antibodies directed against
T. pallidum. Since there is currently no vaccine for syphilis,
antigenic proteins, particularly membrane proteins, continue
to be a focus for investigation.
While T. pallidum evokes strong humoral and cellular
responses in infected humans and rabbits, studies have
shown that the outer membrane appears, paradoxically, to
have limited antigenic reactivity in the intact organism and to
contain relatively few protein molecules (6, 27, 31, 34, 42,
51). However, the fragility of the outer membrane may allow
the exposure of underlying antigens (e.g., periplasmic fla-
gella) to specific antibodies. Although separation of the inner
and outer membranes of T. pallidum has not yet been
achieved, simple cell fractionation studies have shown that a
number of proteins are associated with the whole-membrane
fraction (40). Radolf et al. (33) and Cunningham et al. (11)
have used phase partitioning with the nonionic detergent
Triton X-114 to identify and characterize pathogen-specific
integral membrane proteins from whole T. pallidum cells.
Investigations with treponemes incubated in the presence of
3H-labeled fatty acids have shown that many of these highly
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immunogenic detergent-phase proteins (DPPs) are lipopro-
teins (8, 38). Additionally, Baker-Zander et al. have demon-
strated that certain of these lipoprotein antigens stimulate a
proliferative response in splenic lymphocytes obtained from
syphilitic rabbits (2). Since the cellular immune response
may be of particular importance in the clearance of T.
pallidum from early lesions and in the control of infection
(21, 37), the identification of treponemal lipoproteins has
generated considerable interest. The genes encoding T.
pallidum lipoproteins of 47, 42, 34, and 15 kDa have been
cloned, and the recombinant proteins have been purified and
characterized in further detail (9, 19, 32, 38, 46).
To date, all reported studies of the cloning of T. pallidum
DNA and the majority of studies dealing with the pathogen-
esis of syphilis have used the Nichols strain of T. pallidum.
This strain, which was isolated in 1912 from the cerebrospi-
nal fluid of a patient with recurrent neurosyphilis, has been
maintained by successive passage in laboratory rabbits (49).
Although the Nichols strain remains virulent for humans
(15), it is not known how representative it is of current
clinical isolates of T. pallidum. We have constructed a
cosmid library of genomic DNA from a relatively recent
(1977) clinical isolate of T. pallidum, designated street strain
14 (44), and have identified a clone expressing a treponemal
lipoprotein of approximately 35.5 kDa. The native counter-
part of this protein partitions into the detergent phase from
Triton X-114-fractionated T. pallidum cells, suggesting that
it is an integral membrane protein. The highly immunogenic
nature, membrane location, and pathogen specificity of the
35.5-kDa lipoprotein have prompted our further investiga-
tion of this antigen.
MATERIALS AND METHODS
Bacterial strains and growth conditions. T. pallidum
Nichols and street strain 14 (43, 44) were cultivated, har-
vested, and purified as previously described (40, 41, 43).
Escherichia coli HB101 and CC118 (23) were grown in Luria
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broth (LB) (25) or LB containing (in micrograms per millili-
ter) ampicillin (100), tetracycline (20), chloramphenicol
(100), or kanamycin (300) for selection of transductants or
transformants.
Chemicals and reagents. Phenylmethylsulfonyl fluoride,
protein A-Sepharose, amino acids, 5-bromo-4-chloro-3-in-
dolyl phosphate, and other chemicals were obtained from
Sigma Chemical Co., St. Louis, Mo. Unlabeled molecular-
size standards were obtained from Bio-Rad Laboratories,
Richmond, Calif. Restriction enzymes were obtained from
Bethesda Research Laboratories, Inc., Gaithersburg, Md.;
Boehringer Mannheim Biochemicals, Indianapolis, Ind.; and
Promega, Madison, Wis. T4 DNA ligase was obtained from
Bethesda Research Laboratories; calf intestine alkaline
phosphatase was obtained from Boehringer Mannheim Bio-
chemicals; Tran35S-label (1,153 Ci/mmol) was obtained from
ICN Biomedicals, Inc., Irvine, Calif.; and 9,10(n)-[3H]pal-
mitate (54 Ci/mmol) was obtained from Amersham, Arling-
ton Heights, Ill. Freund's adjuvant was purchased from
Difco Laboratories, Detroit, Mich. Rabbit antiserum to
alkaline phosphatase was obtained from 5 Prime-3 Prime,
Inc., West Chester, Pa.
Preparation of chromosomal and plasmid DNAs. T. palli-
dum street strain 14 cells were gradient purified as previ-
ously described (4), and high-molecular-weight chromo-
somal DNA was prepared by the method of Saito and Miura
(36). Plasmid DNA was prepared by the method of Birnboim
and Doly (5). Competent E. coli cells were prepared by the
method of Hanahan (17). Plasmids pHC79 (18) and pBR328
(39) were obtained from Boehringer Mannheim, and plasmid
pBS was obtained from Stratagene, La Jolla, Calif. DNA
manipulations were carried out according to the methods of
Maniatis et al. (22).
Cosmid cloning. T. pallidum street strain 14 chromosomal
DNA was partially digested with Sau3A, and fragments were
ligated into the BamHI site of pHC79 that had been dephos-
phorylated with calf intestine alkaline phosphatase. Ligation
reactions were packaged in vitro by using GIGA-GOLD
extracts, as described in the Stratagene technical manual.
The recombinant phage particles were transduced into cells
of E. coli HB101 to allow screening for clones expressing T.
pallidum antigens. Rapid plasmid preparations on approxi-
mately a dozen clones from the library demonstrated insert
sizes of 35 to 45 kb.
Identification of clones expressing recombinant T. pallidum
antigens. Recombinant clones were plated on LB agar
containing ampicillin, transferred to nitrocellulose filters
(Schleicher & Schuell, Keene, N.H.), lysed with chloroform
vapor, and screened for expression of treponemal antigens
by using experimental rabbit syphilitic serum (ERSS) and
the Lambda Lift expression detection kit (Bio-Rad Labora-
tories). Positive clones were analyzed by radioimmunopre-
cipitation as follows. Isolated colonies of clones grown on
LB agar containing ampicillin were removed from the agar
and suspended in M9 labeling medium without Casamino
Acids (supplemented with 0.43 mM proline and 1 mM
leucine) (35). The cells were washed once in M9 labeling
medium and suspended in the same medium to an optical
density at 600 nm of 0.5 on a Spectronic 20 spectrophotom-
eter (Bausch & Lomb, Rochester, N.Y.). Cultures (2 ml)
which were starved of methionine by incubation at 37°C for
30 min were then labeled with 25 ,uCi of Tran35S-label per ml
for 45 min. The cells were washed twice with 10 mM Tris
(pH 8.0), suspended in 200 ,ul of 10 mM Tris-1 mM
EDTA-1% sodium dodecyl sulfate (pH 7.5) (TE-SDS) con-
taining 2 mM phenylmethylsulfonyl fluoride, boiled for 3
min, and centrifuged at room temperature for 10 min to pellet
cell debris. Aliquots of the supernatants containing the
radiolabeled proteins were immunoprecipitated in the pres-
ence of 2 mM phenylmethylsulfonyl fluoride, as previously
described (40), with normal rabbit serum (NRS) or ERSS
that had been exhaustively preabsorbed with a lysate of E.
coli HB101 cells containing pHC79. Phenylmethylsulfonyl
fluoride was added to the elution buffer to a final concentra-
tion of 2 mM. Samples were analyzed by SDS-polyacryl-
amide gel electrophoresis (PAGE) and fluorography as pre-
viously described (43).
Preparation of rabbit anti-35.5-kDa-protein serum. Solubi-
lized extracts of unlabeled E. coli cells containing plasmid
pCH1 were prepared as described above and immunoprecip-
itated (40). The immunoprecipitates were eluted from the
protein A-Sepharose pellet with 60 [l of 0.2 M glycine (pH
2.2) at room temperature for 20 min and then centrifuged for
10 min. The supernatants were removed and neutralized (to
pH 7.0) with 1 M Tris-10 mM EDTA (pH 8.0). A 0.6-ml
aliquot of supernatant was mixed with 0.4 ml of phosphate
buffered saline (pH 7.4) and 1 ml of Freund's complete
adjuvant by vigorous mixing on a 5100 Spex mixer-mill
(Spex Industries, Inc., Edison, N.J.) for 15 min at 4°C. A
male New Zealand White rabbit, previously bled to obtain
control serum, was injected intramuscularly with approxi-
mately 0.4 ml of the mixture at each of four sites. Subse-
quent booster injections were performed in the same manner
with Freund's incomplete adjuvant. The rabbit was boosted
four times at 2-week intervals and then again 1 month after
the fourth boost. Blood was collected on the 10th day after
each boost. Reactivity of the serum (at a 1:2,000 dilution)
was assessed by immunoblotting (Vectastain ABC kit, Vec-
tor Laboratories, Burlingame, Calif.) with solubilized T.
pallidum cell extracts that were transferred to nitrocellulose
after SDS-PAGE (48).
Labeling of T. pallidum and other spirochetal species with
Tran35S-label. T. pallidum Nichols and street strain 14 cells
were extracted from infected rabbit testes and intrinsically
labeled with Tran35S-label as previously described (40).
Cells of Treponema phagedenis biotype Reiter, Treponema
denticola, and Leptospira interrogans were grown and in-
trinsically radiolabeled as previously described (28, 40).
Borrelia burgdorferi cells were grown in BSK II medium (3)
supplemented with 5% NRS and radiolabeled overnight in a
modified BSK II medium in which the methionine was
deleted from the CMRL supplement. Labeled cells of the
different species of spirochetes were washed and then solu-
bilized in TE-SDS, and immunoprecipitations were per-
formed and analyzed as previously described (40).
[3H]palmitate radiolabeling of E. coli and T. pallidum
lipoproteins. E. coli and T. pallidum cells were labeled with
[3H]palmitate according to the procedure of Swancutt et al.
(46). The labeled cells were washed, solubilized in TE-SDS,
and immunoprecipitated as previously described (40).
Cell fractionation studies. Triton X-114 phase partitioning
of T. pallidum Nichols was performed by the method of
Radolf et al. (33). Tran35S-labeled organisms (109) were
extracted with 0.2% Triton X-114 (detergent-to-protein ratio
of 10:1). Detergent- and aqueous-phase proteins were ace-
tone precipitated and resuspended in TE-SDS buffer. Immu-
noprecipitations were performed and analyzed as previously
described (40).
Processing studies of the 35.5-kDa lipoprotein. For pulse-
chase studies, E. coli clones were grown in LB containing
ampicillin to an optical density at 600 nm of 0.3. A 6-ml
volume of each culture was removed, pelleted by centrifu-
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gation, washed twice in M9 labeling medium, and suspended
to the original volume in labeling medium. The cells were
starved of methionine by incubation at 37°C for 45 min and
were pulse-labeled with Tran35S-label (40 pCi/ml) for 1 min.
The chase was initiated by the addition of a 0.1 volume of 4%
unlabeled methionine. Samples (0.7 ml) were removed at the
indicated times (min) and added to an equal volume of
ice-cold 10% trichloroacetic acid, and the precipitates were
processed as previously described (12). Immunoprecipitates
of the samples were analyzed by SDS-PAGE with a Tris
buffer system as previously described (43) or with a recircu-
lating phosphate buffer system (20).
For experiments involving the inhibition of processing, E.
coli cells containing pCH1 were grown in LB containing
ampicillin to an optical density at 600 nm of 0.2, pelleted,
washed, and starved of methionine as described above.
Processing inhibitors were individually added to three 1-ml
samples which were incubated as follows: 10% ethanol for 10
min; 5 mM sodium azide for 10 min; or 100 ,ug of globomycin
per ml (dissolved in ethanol; final ethanol concentration of
0.25%) for 5 min. The sodium azide-treated sample was
labeled for 1 min with 40 ,uCi of Tran35S-label per ml; the
other samples were labeled for 15 min. Samples were ace-
tone precipitated and processed as previously described
(12). Immunoprecipitations of the solubilized samples were
performed with anti-35.5-kDa-protein serum and analyzed as
previously described (40).
Isolation of enzymatically active TnphoA insertions into
pCH3. Cells of E. coli CC118 containing pCH3 were grown
in LB with ampicillin to early stationary phase, infected with
ATnphoA-1 (16, 23), and plated on LB agar containing
ampicillin, kanamycin, and 5-bromo-4-chloro-3-indolyl
phosphate (an alkaline phosphatase indicator dye). Plasmid
DNA was prepared from blue colonies and transformed into
CC118 to confirm that the phenotype was plasmid mediated.
Plasmids obtained from repurified blue transformants were
subjected to restriction endonuclease analysis to determine
the position of TnphoA. Selected transformants were labeled
with Tran35S-label as described above. Solubilized cellular
extracts were immunoprecipitated with rabbit anti-35.5-kDa-
protein or anti-alkaline phosphatase serum.
RESULTS
Identification of recombinant clones expressing T. pallidum
protein antigens. A T. pallidum street strain 14 chromosomal
DNA library was constructed. Nine hundred fifty clones
were grown on LB agar containing ampicillin, transferred to
nitrocellulose, and screened for the expression of trepone-
mal antigens. Forty clones tested positive. When these
clones were retested to verify the production of treponemal
antigens, some of them appeared to lose reactivity, likely
because of instability of the recombinant cosmids. The
expression of T. pallidum protein antigens by the remaining,
confirmed-positive clones was analyzed by immunoprecipi-
tation of solubilized, radiolabeled cell extracts with preab-
sorbed ERSS. Several clones expressing unique protein
profiles were identified by SDS-PAGE analysis of the pre-
cipitates.
One of the positive clones, which contained a recombinant
cosmid designated pCH1, was chosen for further investiga-
tion. This clone was of interest because it expressed a single,
strongly antigenic 35.5-kDa protein which appeared as a
cone-shaped band by SDS-PAGE, suggesting that it might be
lipid modified (Fig. 1, lane F). This SDS-PAGE migration
pattern contrasts with that of proteins which are not lipid
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FIG. 1. Radioimmunoprecipitation of the 35.5-kDa recombinant
T. pallidum street strain 14 protein encoded by pCH1. Immunopre-
cipitations were performed as described in the text and analyzed by
SDS-PAGE and fluorography (40). Tran35S-labeled, solubilized T.
pallidum Nichols extract (lane A) was precipitated with NRS (lane
B) or ERSS (lane C). Tran35S-labeled, solubilized E. coli cells
containing pCH1 (lane D) were precipitated with NRS (lane E) or
ERSS (lane F). Tran35S-labeled, solubilized E. coli cells containing
pLVS3, which expresses the 39-kDa treponemal basic membrane
protein (12), were precipitated with NRS (lane G) or ERSS (lane H).
Molecular-size standards are in kilodaltons. The position of the
35.5-kDa protein is indicated by the arrow.
modified, such as the T. pallidium 39-kDa basic membrane
protein (Fig. 1, lane H) that was characterized by Dallas et
al. (12).
Production of specific, polyclonal antiserum against the
35.5-kDa T. pallidum protein. Specific rabbit polyclonal
antiserum was generated against the 35.5-kDa treponemal
protein to facilitate its further characterization. After the
first booster injection, the rabbit serum exhibited very strong
reactivity at a 1:2,000 dilution by immunoblotting against the
recombinant 35.5-kDa protein expressed by E. coli cells
containing pCH1, but it showed no reactivity with E. coli
cells containing cosmid pHC79 (Fig. 2, lanes B and A,
respectively). This serum also reacted with a native trepo-
nemal protein in T. pallidum Nichols and T. pallidum street
strain 14 (Fig. 2, lanes C and D). T. pallidum Nichols was
used in the remaining experiments because it is easier to
maintain in rabbits than street strain 14 and because it yields
greater numbers of organisms from infected rabbit tissues.
Because the band observed by immunoblotting of the
35.5-kDa protein was very diffuse, we could not relate the
recombinant protein to a discrete band in the T. pallidum
protein profile. We used radioimmunoprecipitation to cir-
cumvent this problem. The anti-35.5-kDa-protein serum
A E} C D:
FIG. 2. Immunoblot analysis of solubilized extracts of E. coli
and T. pallidum cells with rabbit anti-35.5-kDa-protein serum.
Solubilized extracts of E. coli cells containing pHC79 (lane A), E.
coli cells containing pCH1 (lane B), T. pallidum Nichols (lane C),
and T. pallidum street strain 14 (lane D) were run on an SDS-
polyacrylamide gel, transferred to nitrocellulose, and probed with a
1:2,000 dilution of rabbit polyclonal anti-35.5-kDa-protein serum.
An immunoperoxidase procedure was used to assess reactivity.
Only the relevant area of the blot is shown. Note that the multiple
banding pattern of the 35.5-kDa protein does not necessarily indi-
cate different forms of this protein. A similar banding pattern has
been previously observed in Western blots (immunoblots) of the T.
pallidum 34-kDa lipoprotein (47).
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FIG. 3. Radioimmunoprecipitation of the 35.5-kDa recombinant
and native T. pallidum protein with rabbit polyclonal anti-35.5-kDa-
protein serum. Immunoprecipitations were performed as described
in the text and were analyzed by SDS-PAGE and fluorography.
Solubilized extracts of Tran35S-labeled T. pallidum Nichols (lane A)
and E. coli HB101 containing pCH1 (lane D) were immunoprecipi-
tated with preimmune rabbit serum (lanes B and E, respectively), or
polyclonal antiserum from the same rabbit after immunization with
immunoprecipitates of the recombinant 35.5-kDa treponemal pro-
tein (lanes C and F, respectively). The solubilized E. coli pCH1
extract was also precipitated with ERSS (lane G).
precipitated a protein of comparable size from solubilized,
radiolabeled cellular extracts of both T. palliduim Nichols
and E. coli containing pCH1 (Fig. 3, lanes C and F). This was
the same protein that was originally recognized by ERSS in
solubilized, radiolabeled cellular extracts of E. coli contain-
ing pCH1. Normal preimmune rabbit serum did not react
with the 35.5-kDa protein (Fig. 3, lanes B and E).
Reactivity of human sera with the recombinant 35.5-kDa
protein. Human sera obtained from patients with various
stages of syphilis (43) were used to immunoprecipitate
radiolabeled, solubilized E. coli cells containing pCH1. Sera
from individuals with secondary and latent syphilis reacted
strongly with the 35.5-kDa recombinant treponemal protein.
Pooled normal human sera did not react with this protein
(data not shown).
Specificity of the 35.5-kDa protein to T. pallidum. Solubi-
lized, radiolabeled cell extracts of nonpathogenic Trepo-
nema species and other pathogenic spirochetes (T. phage-
denis biotype Reiter, T. denticola, L. interrogans, and B.
burgdorferi) were immunoprecipitated with the rabbit poly-
clonal anti-35.5-kDa-protein serum. There was no specific
reactivity of this antiserum to any of these spirochetal
species, indicating that the 35.5-kDa protein is likely specific
to pathogenic treponemes (data not shown). It was also of
interest to determine whether the 35.5-kDa protein is found
in T. pertenue, the causative agent of yaws, since this
pathogenic treponeme is very closely related to T. pallidum
(24). Because T. pertenue cells were not available, serum
from a rabbit infected with T. pertenue was used to immu-
noprecipitate solubilized, radiolabeled extracts of E. coli
cells containing pCH1. The anti-T. pertenue serum reacted
with the recombinant 35.5-kDa protein, indicating that this
antigen is common to both T. pallidum and T. pertenue (data
not shown).
Membrane localization of the 35.5-kDa protein in native T.
pallidum and in E. coli containing pCH1. Tran35S-labeled
cells of T. pallidum Nichols were extracted with 0.2% Triton
X-114, and the solubilized material was partitioned into
detergent and aqueous phases. Although many of the cellular
proteins were insoluble in the Triton X-114 or remained
present in the aqueous phase, a limited number of proteins
were present in the detergent phase, as previously described
by Radolf et al. (33) and Cunningham et al. (11), thus
identifying them as integral membrane proteins (Fig. 4, lane
A). Immunoprecipitation of the various fractions with ERSS
revealed the profile of antigenic proteins in each fraction
(Fig. 4, lane C for each fraction). Immunoprecipitation with
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FIG. 4. Cellular localization of the native T. pallidum 35.5-kDa
protein by Triton X-114 fractionation of Tran15S-labeled T. pallidum
Nichols cells. The insoluble, aqueous, and detergent fractions of
radiolabeled treponemal cells were prepared as described in the
text. The presence of the native 35.5-kDa protein in each fraction
was evaluated by immunoprecipitation with rabbit anti-35.5-kDa-
protein serum. Lanes: A, treponemal fraction; B, precipitate of the
fraction obtained with NRS; C, precipitate obtained with ERSS; D,
precipitate obtained with rabbit anti-35.5-kDa-protein serum. Note
that an NRS control is presented only for the insoluble fraction (lane
B). The position of the 35.5-kDa protein is marked with an arrow.
the anti-35.5-kDa-protein serum demonstrated that the 35.5-
kDa protein is present in both the insoluble material and the
detergent phase but is completely absent from the aqueous
phase (Fig. 4, lane D for each fraction). Note that the few
proteins precipitated from the aqueous phase by the anti-
35.5-kDa-protein serum also were precipitated by the preim-
mune serum from the same rabbit. However, the preimmune
serum did not precipitate any proteins from the detergent
phase (data not shown).
Radiolabeled E. coli cells containing cosmid pCH1 were
disrupted by sonication and ultracentrifuged to separate the
soluble fraction from the whole-membrane pellet as previ-
ously described (40). Immunoprecipitation of the fractions
with anti-35.5-kDa-protein serum showed that the majority
of the recombinant 35.5-kDa protein is associated with the
whole-membrane fraction of E. coli (data not shown).
3H-fatty acid labeling of the 35.5-kDa protein shows it is a
lipoprotein. Most of the Triton X-114 DPPs of T. pallidum
have been shown to be lipoproteins (8). To investigate
whether the 35.5-kDa T. pallidum protein is lipid modified,
E. coli cells containing pCH1 were metabolically labeled
with [3H]palmitate. The labeled cellular proteins were solu-
bilized and analyzed by SDS-PAGE and fluorography.
[3H]palmitate was incorporated into a subset of E. coli
proteins, among which the recombinant 35.5-kDa trepone-
mal protein was clearly visible (Fig. 5, top panel, lane B).
The 35.5-kDa lipoprotein was absent from [3H]palmitate-
labeled E. coli cells containing only pHC79 (Fig. 5, top
panel, lane A). Immunoprecipitation of the [3H]palmitate-
labeled proteins with preabsorbed ERSS confirmed the
treponemal origin of the 35.5-kDa lipoprotein (Fig. 5, top
panel, lane G). Additionally, rabbit polyclonal anti-35.5-
kDa-protein serum specifically recognized the [3Hlpalmitate-
labeled 35.5-kDa lipoprotein from solubilized extracts of
cells containing pCH1 (Fig. 5, top panel, lane F) but not from
extracts of cells containing cosmid pHC79 (Fig. 5, top panel,
lane D). 3H-fatty acid labeling of recombinant treponemal
proteins has previously been shown to represent specific
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FIG. 5. Radiolabeling of the recombinant and native 35.5-kDa T.
pallidum protein with [3H]palmitate. (Top panel) E. coli HB101 cells
containing pHC79 (lane A) or pCH1 (lane B) were radiolabeled with
[3H]palmitate. The solubilized cellular extracts of E. coli(pHC79)
were precipitated with preimmune NRS (lane C) or rabbit anti-35.5-
kDa-protein serum (lane D). The solubilized cellular extracts of E.
coli(pCH1) were precipitated with preimmune NRS (lane E), rabbit
anti-35.5-kDa-protein serum (lane F), or ERSS (lane G). Precipitates
were analyzed by SDS-PAGE and fluorography. The arrow indi-
cates the position of the recombinant 35.5-kDa lipoprotein. (Bottom
panel) T. pallidum Nichols cells were labeled with [3H]palmitate
(lane A). The solubilized cellular extracts were precipitated with
NRS (lane B), anti-35.5-kDa-protein serum (lane C), or ERSS (lane
D). Precipitates were analyzed by SDS-PAGE and fluorography.
Molecular-size standards are in kilodaltons. The arrow indicates the
position of the native T. pallidum 35.5-kDa lipoprotein, which is
clearly visible in lane C but only faintly visible in lane D.
covalent incorporation of the fatty acid into lipid moieties of
the proteins rather than degradation of the fatty acids and
nonspecific incorporation into amino acids (8, 46). We also
radiolabeled cells of T. pallidum Nichols with [3H]palmitate.
Immunoprecipitation of solubilized extracts of the labeled
treponemal cells with anti-35.5-kDa-protein serum con-
firmed that the native protein is lipid modified (Fig. 5, bottom
panel, lane C).
Processing of the 35.5-kDa lipoprotein. The lipid modifica-
tion and the membrane location of the 35.5-kDa lipoprotein
suggested that the protein might be made as a higher-
molecular-mass precursor and then processed to a smaller
mature form by signal sequence cleavage during transloca-
tion across the cytoplasmic membrane. In pulse-chase stud-
ies of E. coli cells containing pCH1, the recombinant 35.5-
kDa lipoprotein did not appear to be processed. When
immunoprecipitates were visualized by SDS-PAGE and flu-
orography, the lipoprotein migrated identically at all time
points (Fig. 6, panel A). A pulse time as short as 15 s did not
reveal the presence of a precursor to the 35.5-kDa lipopro-
tein (data not shown). Another recombinant treponemal
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FIG. 6. Pulse-chase analysis of the recombinant 35.5-kDa T.
pallidum street strain 14 lipoprotein. E. coli HB101 cells containing
either pCH1 (panel A) or pLVS3 (panel B) were pulse-labeled with
Tran35S-label for 1 min. At the indicated chase times (minutes),
samples were removed, processed, immunoprecipitated with ERSS,
and analyzed by SDS-PAGE and fluorography.
FIG. 7. Inhibition of processing of the 35.5-kDa recombinant
treponemal lipoprotein. E. coli cells containing pCH1 were treated
with protein processing or translocation inhibitors prior to labeling
with Tran35S-label. Solubilized extracts of the labeled samples were
precipitated with anti-35.5-kDa-protein serum and analyzed by
SDS-PAGE and fluorography. Lanes: A, untreated control; B, 10%
ethanol; C, globomycin; D, sodium azide. The two arrows indicate
the respective positions of the precursor and the smaller mature
form of the 35.5-kDa lipoprotein.
protein, the 39-kDa basic membrane protein, which is known
to be processed in E. coli (12), was labeled in a parallel
pulse-chase experiment, and immunoprecipitates were ana-
lyzed on the same gel. The 39-kDa basic membrane protein
clearly showed processing from a higher- to a lower-molec-
ular-mass form (Fig. 6, panel B). Immunoprecipitates of
solubilized E. coli cells containing pCH1 from the pulse-
chase experiment also were analyzed by SDS-PAGE with a
sodium phosphate buffer system, which has been demon-
strated to resolve precursor and mature E. coli Braun
lipoprotein (20). Again, no processing was apparent (data not
shown).
Protein export or processing can be inhibited by the
exposure of cells to ethanol, sodium azide, or globomycin.
Ethanol acts as a membrane perturbant and inhibitor of
protein translocation (30). Sodium azide, at low concentra-
tions, specifically inhibits export of SecA-dependent pro-
teins (29). Globomycin is known to be an inhibitor of
lipoprotein-specific signal peptidase 11 (13). When E. coli
cells containing pCH1 were individually treated with these
compounds prior to radiolabeling, the presence of a precur-
sor of the 35.5-kDa lipoprotein with a slightly higher molec-
ular mass was detected after immunoprecipitation of the
solubilized cellular extracts (Fig. 7). These results indicated
that the 35.5-kDa lipoprotein is processed from a precursor
to a mature form. Failure to detect a precursor form in the
pulse-chase experiments must be due to very rapid process-
ing of the 35.5-kDa lipoprotein in E. coli.
Subcloning and restriction mapping of pCH1. Plasmid
pCH1 was isolated and digested with the restriction enzyme
Hindlll, and the resulting fragments were cloned into the
HindIlI site of plasmid pBR328. Subclones were screened by
immunoassay with preabsorbed ERSS and an alkaline phos-
phatase detection system. The gene expressing the 35.5-kDa
protein was found to be contained in a 3.8-kb HindlIl
fragment of treponemal DNA. This construct was designated
pCH2. A restriction map of pCH2 was generated (Fig. 8).
The following restriction enzymes did not cut within the
treponemal DNA insert: BamHI, HpaI, KpnI, NdeI, Sacl,
SmaI, and XhoI. A fragment of the pCH2 treponemal insert
extending from the StuI site to the left-hand HindlIl site was
subcloned into plasmid pBS+ in both orientations, generat-
ing plasmids pCH3 and pCH4. The 35.5-kDa lipoprotein was
expressed by both pCH3 and pCH4, suggesting that the
treponemal DNA fragment likely contains a promoter that is
functional in E. coli.
Fusion of alkaline phosphatase to the 35.5-kDa T. paUidum
lipoprotein. We have used a gene fusion approach employing
42.6-
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FIG. 8. Restriction map of plasmid pCH2, a subclone of pCH1
that encodes the 35.5-kDa recombinant T. pallidum street strain 14
lipoprotein. The arrow indicates the direction of transcription and
approximate location of the gene encoding the 35.5-kDa lipoprotein.
The position of TnphoA insertion in subclone pCH3 is indicated (A).
the transposon TnphoA, which contains the E. coli phoA
gene encoding alkaline phosphatase but lacking its signal
sequence, to identify genetic sequences in pCH3 that encode
protein export signals. A hybrid protein produced by fusion
with TnphoA expresses alkaline phosphatase activity if the
target gene encodes a signal that facilitates extracytoplasmic
localization of the protein. Cells of E. coli CC118 (PhoA-)
carrying pCH3 were infected with XTnphoA-1, and dark blue
(PhoA+) colonies were detected on LB agar containing
selective antibiotics and 5-bromo-4-chloro-3-indolyl phos-
phate. Plasmid DNA was prepared from the blue colonies
and retransformed into cells of E. coli CC118; four small
colonies were obtained that stably expressed the PhoA+
phenotype. Analysis of plasmid preparations from the blue
transformants produced identical restriction patterns, indi-
cating that TnphoA was present within the treponemal DNA
insert of pCH3, at the same position in each case. The
position of the transposon in pCH3 is indicated on the map of
pCH2 (Fig. 8). One of the transformants, designated B2, was
chosen for further study. Solubilized extracts of Tran35S-
labeled cells of B2 were immunoprecipitated with antiserum
against the 35.5-kDa lipoprotein or alkaline phosphatase. As
seen in Fig. 9, both sera precipitated a fusion protein of
approximately 61 kDa representing a 35.5-kDa lipoprotein-
PhoA hybrid. These results clearly demonstrated that the
35.5-kDa T. pallidum lipoprotein contains a sequence that
promotes protein export, thus facilitating extracytoplasmic
localization of the fusion protein. By determining the orien-
tation of TnphoA in pCH3 (Fig. 8), we also learned the
direction of transcription of the gene encoding the 35.5-kDa
lipoprotein.
DISCUSSION
We have constructed a genomic DNA library from a
relatively recent clinical isolate of T. pallidum, designated
street strain 14. This strain was obtained in 1977 from a
patient with active secondary syphilis who failed to respond
to erythromycin therapy (44). SDS-PAGE analysis of the
polypeptide profiles from a very limited number of street
strains, including street strain 14, has revealed that there are
minor differences between these strains and the Nichols
42.6 --
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FIG. 9. Radioimmunoprecipitation of a 35.5-kDa lipoprotein-
PhoA fusion protein generated by TnphoA insertion into pCH3. E.
coli CC118 cells containing pCH3 (lanes A and B) or pCH3 with a
TnphoA insertion in the treponemal DNA fragment encoding the
35.5-kDa lipoprotein (lanes C and D) were labeled with Tran35S-
label, solubilized, and precipitated with anti-35.5-kDa-protein serum
(lanes A and C) or anti-alkaline phosphatase serum (lanes B and D).
Precipitates were analyzed by SDS-PAGE and fluorography as
previously described.
strain (10, 40). Additionally, we have previously reported
that physiologic differences exist between street strain 14
and the Nichols strain. Cells of street strain 14 exhibit
high-level erythromycin resistance and are generally less
susceptible to a variety of antibiotics than are cells of the
Nichols strain (44).
While screening our street strain 14 library for clones
expressing T. pallidum antigens, we identified a clone ex-
pressing a strongly antigenic 35.5-kDa protein. The unique,
cone-shaped banding profile of the protein by one-dimen-
sional SDS-PAGE suggested that it might be a lipoprotein
and that it warranted further investigation. Using antiserum
generated against the 35.5-kDa protein, we identified pro-
teins of similar sizes in both street strain 14 and the Nichols
strain of T. pallidum. The native treponemal protein corre-
sponding to the recombinant 35.5-kDa protein partitioned in
the detergent phase from T. pallidum cells extracted with
Triton X-114. Chamberlain et al. (8) demonstrated that most
of the treponemal DPPs are lipoproteins. Radiolabeling of
the recombinant 35.5-kDa protein and its native counterpart
with [3H]palmitate confirmed that this protein is lipid modi-
fied. The 35.5-kDa lipoprotein that we have identified may be
identical to the 36-kDa lipoprotein observed in the 3H-fatty
acid-labeled protein profile of T. pallidum reported by Cham-
berlain et al. (8) or the 35-kDa lipoprotein observed in the T.
pallidum DPP profile of Cunningham et al. (11).
Although the partitioning of the native 35.5-kDa lipopro-
tein into the Triton X-114 detergent phase suggests that it is
an integral membrane protein, the precise cellular location of
this protein remains in question, as does that of the other T.
pallidum DPPs. Some of these proteins, namely the 47- and
34-kDa lipoproteins, were originally reported to be cell
surface exposed by a number of criteria that were subse-
quently found to be somewhat problematic (19, 47). More
recent techniques, such as freeze-fracture and freeze-etch
electron microscopy, have suggested that the T. pallidum
outer membrane contains a paucity of protein (34, 51).
However, proteins anchored to membranes by lipid moieties
would not be detected by these techniques.
Purcell et al. and Swancutt et al. have shown that the 34-
and 15-kDa treponemal lipoproteins are synthesized as high-
er-molecular-mass precursors that are processed to a lower-
molecular-mass mature form (32, 46, 47). Schouls et al. (38)
demonstrated that a 42-kDa T. pallidum lipoprotein (TmpA)
is also processed from a precursor to a mature form.
Globomycin, a selective inhibitor of the lipoprotein-specific
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signal peptidase II, abolished the processing of the 42-, 34-,
and 15-kDa lipoproteins in E. coli (32, 38, 46). We could not
detect processing of the recombinant 35.5-kDa treponemal
lipoprotein by pulse-chase studies using standard SDS-
PAGE analysis or employing a sodium phosphate buffer
system which resolved the precursor and mature forms of
the E. coli Braun lipoprotein (20). However, when we
pretreated E. coli cells containing pCH1 with inhibitors of
protein processing or export, such as ethanol, sodium azide,
or globomycin, we detected a precursor form of the 35.5-kDa
lipoprotein. Furthermore, studies of the fusion of the 35.5-
kDa lipoprotein to signal sequence-deficient alkaline phos-
phatase clearly demonstrated that this lipoprotein contains
an export signal, presumably a signal sequence, that pro-
motes the extracytoplasmic localization of the hybrid pro-
tein. A 47-kDa lipoprotein that has been extensively studied
by Chamberlain et al. is an example of a T. pallidum integral
membrane protein that, on the basis of the results of pulse-
chase studies, also does not appear to undergo processing in
E. coli (9). Treatment of T. pallidum cells with globomycin
did not reveal a precursor form of this lipoprotein (46).
Several investigators have reported the identification of
clones expressing treponemal protein antigens within the
molecular-size range of the 35.5-kDa lipoprotein (1, 26, 43).
Isolation of a clone expressing a 35-kDa T. pallidum Nichols
protein (TmpC) that bears some resemblance to the 35.5-kDa
protein was reported by van Embden et al. (50). More
recently, Bailey et al. have reported the isolation of a
recombinant plasmid (pMJB40) encoding a 29-kDa T. palli-
dum protein that likely represents a truncated form of the
35-kDa protein, since monoclonal antibody that recognizes
this protein also appears to recognize TmpC (1). Unfortu-
nately, the information available for TmpC is incomplete.
TmpC is membrane associated, does not react with antise-
rum to the nonpathogenic Reiter treponeme, labels with
[3H]palmitate, and has a banding pattern by SDS-PAGE
similar to that of the 35.5-kDa lipoprotein that we have
characterized (38, 50). Preliminary sequence data suggest
that TmpC has a signal sequence and a signal peptidase II
cleavage site (38). Since a restriction map for the gene
encoding TmpC has not been published, we compared our
restriction map for pCH2 with that for pMJB40. Substantial
differences that are not explained by the truncated nature of
the gene exist. For example, pMJB40 lacks two PstI sites
found to the left of the central ClaI site in pCH2. Further-
more, pMJB40 contains a PvuII site close to the ClaI site
which is absent from pCH2. If these clones contain the same
gene, the restriction site differences would likely be due to
differences in the DNA sequences of T. pallidum street
strain 14 and Nichols.
The development of an effective vaccine to prevent infec-
tion with T. pallidum has been a major long-term goal of
syphilis researchers. It is hoped that recombinant DNA
technology will facilitate this endeavor. However, attempts
to immunize animals with recombinant T. pallidum proteins
have failed to induce protective immunity (7, 45, 52). Be-
cause of the highly immunogenic nature, membrane loca-
tion, and pathogen specificity of the 35.5-kDa lipoprotein,
we initiated studies to determine the effect of immunization
with this antigen on the clinical course of syphilis in the
rabbit model. Our preliminary results suggest that immuni-
zation with the 35.5-kDa lipoprotein alters the response of
rabbits to experimental syphilitic infection (19a). We think
that these observations are of sufficient interest to warrant
further investigation. Studies are currently under way in our
laboratories to sequence the gene encoding the 35.5-kDa T.
pallidum lipoprotein. Analysis of the DNA sequence should
provide further insight into the processing and maturation of
this pathogen-specific antigen. Additionally, such informa-
tion will likely prove useful in the development of strategies
to enhance the expression of the recombinant 35.5-kDa
lipoprotein in E. coli, thus facilitating purification and further
characterization of its vaccinogenic or diagnostic potential.
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